CATALOGO DEI PRODOTTI DELLA RICERCA

DE NITTO, SIMONE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.287
EU - Europa 1.695
AS - Asia 1.447
SA - Sud America 190
AF - Africa 64
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.689
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.234
RU - Federazione Russa 868
SG - Singapore 638
CN - Cina 269
IT - Italia 222
BR - Brasile 158
HK - Hong Kong 158
VN - Vietnam 144
FR - Francia 105
DE - Germania 99
IE - Irlanda 87
GB - Regno Unito 83
SE - Svezia 70
KR - Corea 66
FI - Finlandia 49
BD - Bangladesh 47
ES - Italia 34
CA - Canada 29
IN - India 26
JP - Giappone 21
TG - Togo 19
PL - Polonia 18
ID - Indonesia 16
BJ - Benin 14
MX - Messico 13
NL - Olanda 10
LT - Lituania 9
NG - Nigeria 9
AR - Argentina 8
IQ - Iraq 8
PH - Filippine 8
AT - Austria 7
BE - Belgio 7
UA - Ucraina 7
VE - Venezuela 7
CO - Colombia 6
TR - Turchia 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
EC - Ecuador 5
IR - Iran 5
MA - Marocco 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
PY - Paraguay 4
AZ - Azerbaigian 3
CH - Svizzera 3
JO - Giordania 3
KE - Kenya 3
SA - Arabia Saudita 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
OM - Oman 2
RS - Serbia 2
TN - Tunisia 2
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
IS - Islanda 1
LK - Sri Lanka 1
LV - Lettonia 1
MG - Madagascar 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SV - El Salvador 1
TH - Thailandia 1
Totale 5.689
Salva come PNG Salva come JPEG
Città #
Singapore 376
Ashburn 353
Dallas 313
San Jose 308
Moscow 264
Chandler 260
Hong Kong 156
The Dalles 111
Verona 88
Dublin 84
Beijing 61
Ho Chi Minh City 57
Council Bluffs 56
Munich 47
Los Angeles 45
Redmond 37
Columbus 33
New York 32
Hanoi 30
Buffalo 29
Lawrence 25
Princeton 25
London 24
Helsinki 23
Madrid 23
Seattle 23
Sindelfingen 20
Lomé 19
Santa Clara 19
Tokyo 19
Wilmington 19
Redondo Beach 18
Seoul 18
Turku 16
Orem 15
São Paulo 15
Cotonou 14
Brooklyn 12
Jakarta 12
Milan 12
Montreal 12
Poplar 12
Southend 11
Warsaw 11
Frankfurt am Main 10
Jacksonville 10
Lappeenranta 10
Rome 10
Abuja 9
Atlanta 8
Paris 8
Phoenix 8
Ancona 7
Ann Arbor 7
Boston 7
Brussels 7
Chicago 7
Denver 7
Houston 7
Hải Dương 7
Amsterdam 6
Brasília 6
Chennai 6
Guangzhou 6
Tashkent 6
Vienna 6
Bonndorf 5
Da Nang 5
Haiphong 5
Hangzhou 5
Mexico City 5
Washington 5
Baghdad 4
Bexley 4
Biên Hòa 4
Calgary 4
Charlotte 4
Dhaka 4
Fairfield 4
Johannesburg 4
Norwalk 4
Padova 4
Peschiera del Garda 4
Querétaro 4
San Francisco 4
Shanghai 4
Stockholm 4
Tianjin 4
Woodbridge 4
Amman 3
Ankara 3
Asunción 3
Baku 3
Campinas 3
Can Tho 3
Caracas 3
Caxias do Sul 3
Changsha 3
Curitiba 3
Dongguan 3
Totale 3.453
Salva come PNG Salva come JPEG
Nome #
Bile Acids Quantification by Liquid Chromatography-Tandem Mass Spectrometry: Method Validation, Reference Range, and Interference Study 205
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 192
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 181
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 168
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 167
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 160
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 157
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 156
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 155
Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay 151
Thrombin Generation in Patients with Coronavirus Disease 2019 148
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 147
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 147
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 141
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 140
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 138
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 136
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 133
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 131
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 129
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 128
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 128
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 119
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 116
Accuracy of screening for hemolysis in plasma samples using a commercial urine dipstick 115
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 113
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 112
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 112
Monoclonal gammopathy in SARS-CoV-2 infection 110
Cellular immunity against SARS-CoV-2 depends on the serological status 110
Impact of the COVID-19 pandemic on the volume of laboratory testing 108
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 101
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 100
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 98
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 98
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 95
Evaluation of the acceptability of proposed hemolysis limits for Werfen ACL-TOP 750 CTS 93
Impact of water temperature on reconstitution of quality controls for routine hemostasis testing 92
Machine learning model comparison in the screening of cholangiocarcinoma using plasma bile acids profiles 87
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 85
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 85
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 81
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 74
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 69
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 69
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 68
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 67
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 62
Niveles séricos de antígeno prostático específico (PSA) tras vacunación primaria con BNT162b2 5
Impacto de la vacunación primaria con BNT162b2 y una dosis de refuerzo homóloga en los anticuerpos IgA contra SARS-CoV-2 en profesionales sanitarios seronegativos 5
Variación longitudinal comparativa de los anticuerpos totales, IgG e IgA contra el SARS-CoV-2 en receptores de la vacuna BNT162b2 4
Son los anticuerpos IgG e IgM contra los antígenos S y N del SARS-CoV-2 siempre predictores de infección previa por SARS-CoV-2? 3
Totale 5.794
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.829
article - articoli 22.474
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 355
Totale 45.658
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 0 0 0 0 0 0 0 0 0 0 0 27
2021/2022228 31 44 7 9 12 7 5 7 17 7 27 55
2022/2023659 37 55 58 120 37 138 23 59 67 9 30 26
2023/2024408 20 30 19 46 61 50 44 64 3 22 39 10
2024/20251.091 59 72 41 165 54 55 34 58 135 98 131 189
2025/20263.323 220 189 275 504 811 212 331 181 215 148 125 112
Totale 5.794